Genetic counseling & PGT results review for informed embryo transfer decisions
Preimplantation genetic testing (PGT) generates a dense layer of information about each embryo from a single IVF cycle. Before any decision can be made, results from PGT-A (aneuploidy screening), PGT-M (single-gene disorder testing) and standard morphology grading must be compiled into one coherent cohort view — the starting point for every downstream conversation.
Preimplantation genetic testing is performed on a small trophectoderm biopsy (5–10 cells) taken from a day-5, -6 or -7 blastocyst, never from the inner cell mass that becomes the fetus itself. Next-generation sequencing (NGS) of the biopsy quantifies relative chromosome copy number across all 24 chromosome types.
Three related but distinct tests are commonly bundled under "PGT":
• PGT-A (aneuploidy): screens for whole- or partial-chromosome gains and losses — the leading cause of implantation failure and miscarriage, and the primary driver of age-related fertility decline. • PGT-M (monogenic/single-gene): targets a specific familial mutation — in this simulated cohort, both intended parents carry one copy of the CFTR ΔF508 mutation for cystic fibrosis, an autosomal recessive condition, giving each embryo a 25% unaffected / 50% carrier / 25% affected Mendelian probability. • PGT-SR (structural rearrangement): screens embryos of a parent carrying a balanced translocation or inversion for unbalanced chromosome segments.
A trophectoderm biopsy result is a statistical estimate of the whole embryo's chromosome status, not a certainty — biopsy accuracy for the inner cell mass is estimated at roughly 97% for clearly euploid or aneuploid calls, which is why mosaic and borderline results demand extra caution.
Every biopsy report sorts an embryo into one of four PGT-A categories:
• Euploid — the normal 46-chromosome complement is detected in essentially all sampled cells. Statistically the highest-priority category for transfer. • Low-level mosaic — an estimated 20–40% of sampled cells carry an abnormal chromosome complement alongside a euploid majority. Mosaicism arises from mitotic errors after fertilization, meaning different cells within the same embryo can carry different karyotypes. • High-level mosaic — an estimated 40–80% abnormal cell fraction. Considered lower-priority and more uncertain than low-level mosaic. • Aneuploid (non-mosaic) — the abnormal chromosome complement is detected in essentially all sampled cells, consistent with a uniformly abnormal embryo.
Morphology grading (Gardner system) is recorded alongside genetics: an expansion score (1–6), an inner cell mass grade (A–C) and a trophectoderm grade (A–C), e.g. "4AA" denotes a fully expanded blastocyst with top-grade ICM and trophectoderm.
The embryology lab and genetics laboratory each send independent reports; the genetic counselor's first task is reconciling them into a single per-embryo record before any patient conversation happens. A typical cohort dashboard row includes: embryo ID, biopsy day, chromosomal classification, mosaic cell-fraction estimate (if applicable), specific monogenic test result, and morphology grade.
This compiled view — not any single test in isolation — is what makes structured ranking and shared decision-making possible in the next stages. Errors or omissions at this compilation step (mislabeled tubes, incomplete NGS coverage, discordant lab reports) are a recognized source of clinical risk, which is why accredited laboratories follow strict chain-of-custody and dual-verification protocols.
Numbers on a lab report do not, by themselves, make a decision. A genetic counselor's role is to translate probabilistic, sometimes ambiguous genetic information into terms intended parents can actually use — while surfacing the emotional, ethical and practical dimensions that a results printout cannot capture.
Reproductive genetic counselors typically hold a master's degree in genetic counseling and board certification from the American Board of Genetic Counseling (ABGC) or the Canadian Board of Genetic Counselling (CAGC), often working alongside guidance from the American College of Medical Genetics and Genomics (ACMG) and the American Society for Reproductive Medicine (ASRM). Many reproductive endocrinology clinics also involve the treating physician or embryologist for technical questions about biopsy and morphology.
The counselor's job is explicitly not to tell the family what to choose. Non-directive counseling — presenting balanced, accurate information and supporting the family's own value-based decision — is a core professional standard in genetic counseling, distinguishing it from purely medical advice-giving.
A thorough session walks through every embryo in the cohort, not just the "best" ones, because disposition decisions later in the process require the family to understand every result:
• For euploid embryos: expected implantation and live-birth rates, and whether the embryo is a monogenic carrier (unaffected phenotype, but a 50% chance of passing the mutation to future generations if the resulting child later reproduces with another carrier). • For mosaic embryos: the practical meaning of a mixed cell-line result, the uncertainty inherent in a small biopsy sample, and published outcome data showing many mosaic-embryo transfers can result in healthy euploid live births — alongside the honest caveat that outcome data for mosaicism is still maturing. • For aneuploid embryos: why transfer is rarely recommended, and what "rarely" means in practice (some clinics will discuss transfer only under specific circumstances and with extensive additional consent). • For monogenic-affected embryos: exactly what the diagnosed condition means clinically — its severity, treatability and life-course impact — since this varies enormously by disorder.
Non-directive counseling does not mean value-neutral silence. Counselors are trained to actively check understanding ("teach-back"), correct misconceptions about mosaicism and probability, and explicitly invite questions — because informed consent is only meaningful if the information was actually understood.
Embryo results conversations happen after months or years of fertility treatment, often carrying significant financial and emotional weight. Genetic counselors are trained to recognize decision fatigue, grief over unusable embryos, and disagreement between partners — and to slow the process down rather than push toward a single session resolution.
Families frequently need time between the results-review session and the ranking/consent stages that follow. Reputable clinics build this time into the protocol rather than treating counseling as a single transactional checkbox before proceeding to transfer.
Once results are understood, embryos are ordered into a transfer-priority list. The prevailing clinical hierarchy prioritizes chromosomal status first, then uses morphology grade as a tiebreaker among embryos in the same genetic tier — but real cohorts rarely sort themselves cleanly, which is why the relative weighting matters.
Across ASRM and ESHRE (European Society of Human Reproduction and Embryology) guidance documents, the broadly accepted transfer-priority order for a PGT-A-tested cohort is:
1. Euploid embryos — first priority whenever available. 2. Low-level mosaic embryos (roughly 20–40% abnormal cell fraction) — considered next if no euploid embryo is available, generally with additional counseling. 3. High-level mosaic embryos (roughly 40–80% abnormal cell fraction) — lower priority still, reserved for cases with no lower-tier option and extensive informed consent. 4. Aneuploid (non-mosaic) embryos — very rarely transferred; most programs decline to transfer these except in unusual, heavily counseled circumstances.
Within any tier, morphology grade — and increasingly, day of biopsy (day-5 blastocysts are generally viewed as developmentally more robust than day-7) — serves as the tiebreaker.
No single validated formula perfectly predicts implantation outcome from genetics and morphology alone — both matter, but clinics and researchers differ on exactly how much relative weight each deserves, and the "right" answer can shift with the individual family's history (e.g., a patient with a low ovarian reserve and only mosaic embryos available faces a different calculus than one with several euploid options).
The interactive ranking in this simulation lets you shift a weighting slider between "genetic status" and "morphology grade" to see how the composite score — and the resulting order — responds. A very high genetic weighting collapses the list toward the strict euploid > mosaic > aneuploid tiers; a higher morphology weighting can let an excellent-morphology low-mosaic embryo outrank a poor-morphology euploid one, which mirrors real clinical debate about how much developmental "vigor" data should offset genetic uncertainty.
A landmark multi-center study (Victor et al., 2019, Fertility and Sterility) found that transferring mosaic embryos — when no euploid embryo was available — resulted in ongoing pregnancy/live birth in roughly a third to two-fifths of transfers, with no increase in miscarriage rate for low-level mosaics versus euploid controls in that cohort, supporting their cautious, counseled use rather than automatic discard.
The ranking framework produces a transfer-priority order among embryos considered viable candidates. It intentionally does not, by itself, resolve what happens to embryos excluded from the ranked list — aneuploid embryos, monogenic-affected embryos, or (depending on the family's chosen mosaicism tolerance) high-level mosaic embryos. Those embryos still exist, are still the family's property/responsibility, and still require an explicit, separately consented decision. That is the subject of the next stage.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Tier 1 — Euploid | 46 chromosomes detected in sampled cells | Highest reported implantation and live-birth rates | First priority for transfer whenever available |
| Tier 2 — Low-Level Mosaic | ~20–40% abnormal cell fraction estimated | Mixed euploid/aneuploid cell lines from post-fertilization mitotic error | Reasonable live-birth rates reported when no euploid available |
| Tier 3 — High-Level Mosaic | ~40–80% abnormal cell fraction estimated | Larger abnormal cell fraction, more developmental uncertainty | Considered only with extensive consent, no lower tier available |
| Tier 4 — Aneuploid (non-mosaic) | Abnormal complement in essentially all sampled cells | Uniform chromosomal abnormality | Very rarely transferred; usually excluded from ranking |
Every tested cohort produces embryos that will not be transferred in the current cycle — whether because they scored lower in ranking, carry a diagnosed condition, or are chromosomally abnormal. Deciding what happens to them is not a genetics question; it is an ethical and deeply personal one, governed by informed consent rather than clinical algorithm.
ASRM Ethics Committee guidance and standard IVF-clinic consent frameworks recognize a consistent set of options for any embryo not used in the current transfer cycle:
• Transfer — used now or cryopreserved for a future transfer attempt by the same intended parent(s). • Continued cryostorage — indefinite storage (subject to clinic storage-fee agreements) while the family decides. • Donation to research — the embryo is used, with consent, in scientific research (e.g., stem cell derivation, developmental biology) and is not permitted to develop further as a pregnancy. • Donation to another individual or couple ("embryo donation") — a formal, often legally documented process (sometimes called embryo adoption) allowing another family to attempt pregnancy with the embryo. • Discard (thaw without further use) — the embryo is thawed and not used further, following the clinic's disposal protocol.
Each pathway requires its own dedicated, specific consent form — a single blanket consent at IVF cycle start is not considered sufficient for these decisions under ASRM guidance.
This stage is where reasonable people, and reasonable clinical ethics frameworks, genuinely diverge:
• Aneuploid embryos are, in current practice, very rarely transferred — most programs consider this outside standard of care except in narrow, heavily consented circumstances (e.g., a specific mosaic finding later re-classified, or a family declining PGT-informed selection altogether). Some patients nonetheless request transfer be kept as an option; clinics vary in whether and how they accommodate this. • Monogenic-affected embryos (like the CF-affected embryo in this simulated cohort) raise a distinct question from aneuploidy: the condition may be manageable or survivable, and some intended parents — particularly those with lived experience of the condition in their own family — choose to transfer an affected embryo with full informed consent about the expected disease course. This is a legitimate, respected choice within reproductive autonomy frameworks, not an error to be corrected. • Donation to research versus discard is often an emotionally easier choice for families than it may appear on paper — many patients report that "the embryo contributed to science" provides more closure than either indefinite storage or an unspecified discard procedure, though this varies by individual and by cultural/religious background.
ASRM Ethics Committee opinions are explicit that decisions about embryo disposition belong to the individuals who created the embryos, within the bounds of law and clinic policy — the clinical team's role is to ensure the choice is genuinely informed, not to substitute its own judgment about what "should" happen to a given embryo.
A defensible consent process for embryo disposition typically documents: (1) that the classification and its clinical meaning were explained and understood, (2) that all five disposition pathways were presented as genuinely available options (not merely default vs. exception), (3) that the family had adequate time and, where desired, access to further counseling or second opinions, and (4) the signatures of both intended parents/partners, since embryos are typically treated as joint property requiring joint consent for disposition.
Because circumstances change — divorce, death of a partner, years passing without a decision — many clinics also document a contingency plan (e.g., default disposition if the family becomes unreachable) as part of the same consent process.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Transfer | Highest-ranked, consent-cleared embryo(s) | Fresh or frozen embryo transfer to intended parent/gestational carrier | Direct path to pregnancy attempt |
| Continued Cryostorage | Viable, lower-priority embryos | Vitrified storage under annual/ongoing storage agreement | Preserves future family-building options |
| Donation to Research | Non-transferred viable or abnormal embryos | Used under consent for approved research protocols; not used for pregnancy | Contributes to scientific knowledge |
| Donation to Another Family | Viable embryos family will not use | Formal embryo donation / "embryo adoption" program | Enables another family's pregnancy attempt |
| Discard | Aneuploid, affected, or unwanted embryos | Thaw without further use per clinic protocol | Resolves storage/decision burden |
The process converges on a concrete outcome: one embryo designated for the current transfer attempt, a documented plan for every remaining embryo, and signed consent covering both the genetic findings and the disposition choices made. This is the deliverable of the entire counseling process, not merely a ranking exercise.
ASRM guidelines increasingly favor elective single-embryo transfer (eSET), especially for euploid embryos, because it achieves comparable cumulative live-birth rates to multi-embryo transfer while avoiding the substantially higher risks of twin/multiple pregnancy — preterm birth, low birth weight, preeclampsia, and neonatal intensive care admission all rise sharply with multiples.
The ranked list from Stage 3, filtered through the consent decisions from Stage 4, identifies the single best-supported candidate: the highest-scoring embryo that both meets the family's genetic risk tolerance and has cleared consent for transfer.
A complete final record for the cohort specifies, for every single embryo: its classification, its rank (if ranked), and its consented disposition — transfer, cryostorage, research donation, family donation, or discard. Nothing is left as an unresolved default.
Cryopreserved embryos are vitrified (ultra-rapid freezing) rather than slow-frozen in essentially all modern programs, giving post-warming survival rates above roughly 95% for good-quality blastocysts — meaning a cryostorage decision today does not meaningfully compromise a future transfer attempt with that embryo.
The final consent packet typically bundles: the PGT results summary, the ranking rationale, the individually signed disposition form for each non-transferred embryo, and an acknowledgment that the intended parents understand they may revisit disposition decisions later — since ASRM guidance treats these as revisable, not irreversible once signed.
Clinics typically schedule a follow-up point after the transfer attempt (whether it results in pregnancy or not) to revisit the remaining cryopreserved cohort. Family circumstances, values, and even relevant medical evidence (e.g., emerging mosaic-embryo outcome data) can shift over a period of years, and ASRM guidance explicitly supports revisiting disposition decisions rather than treating the original consent as permanently binding.
This closes the loop from Stage 1's raw results panel to a fully documented, ethically grounded, family-directed outcome — the intended purpose of genetic counseling in the PGT pathway.